Value Screen — Estimated Discount to Fair Value
| Company | Ticker | Current P/E | Fair Value P/E | Est. Discount | Catalyst |
|---|---|---|---|---|---|
| Pfizer | PFE | 9x | 15x | -40% | Pipeline commercialization |
| Intel | INTC | 22x | 30x | -27% | Foundry turnaround execution |
| CVS Health | CVS | 8x | 12x | -33% | Healthcare segment restructuring |
| PayPal | PYPL | 14x | 22x | -36% | New CEO execution & buybacks |
| Comcast | CMCSA | 9x | 13x | -31% | Broadband spin-off optionality |
| Verizon | VZ | 8x | 12x | -33% | Fixed wireless 5G market share gains |
| Baidu | BIDU | 8x | 14x | -43% | AI monetization China rerating |
| Warner Bros Discovery | WBD | 12x | 18x | -33% | Streaming profitability turn |
| KeyCorp | KEY | 11x | 16x | -31% | Rate cut NIM recovery |
| Whirlpool | WHR | 8x | 13x | -38% | Housing market recovery |
Value Investing Checklist
- Does the business have durable competitive advantages despite current problems?
- Is the undervaluation due to temporary issues or permanent structural decline?
- Management with skin in the game (insider ownership) aligns incentives
- Balance sheet must be strong enough to survive the wait (low debt, positive FCF)
- Clear catalyst: what will cause the market to re-rate the stock higher?
- Margin of safety: buy at 30%+ discount to conservative intrinsic value estimate
- Avoid "value traps" — cheap for a reason with no identifiable recovery path
Related Reports
Deeper Research
Disclaimer: This report is for informational and educational purposes only. Nothing on this page constitutes financial advice, investment recommendations, or solicitation to buy or sell any security. Past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. Data sourced from public filings and market data providers.